Thromboxane B2 is an inactive metabolite/product of thromboxane A2. It is almost completely cleared in the urine.
It itself is not involved in platelet activation and aggregation in case of a wound, but its precursor, thromboxane A2, is. Thromboxane A2 synthesis is the target of the drug aspirin, which inhibits the COX-1 enzyme (the source of thromboxane A2 in platelets).
Thromboxane is a member of the family of lipids known as eicosanoids. The two major thromboxanes are thromboxane A2 and thromboxane B2.
Thromboxane is named for its role in clot formation (thrombosis).
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN.
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. Epub 2004 Oct 7.
PMID: 15471991
doi: 10.1073/pnas.0405445101